



Join Keystone Symposia
for the 2016 conference on:

Cancer Immunotherapy: Immunity and Immunosuppression Meet Targeted Therapies

January 24–28, 2016

Fairmont Hotel Vancouver | Vancouver, British Columbia | Canada

Scientific Organizers:

Barbara Seliger, Jerome Galon and Francesco M. Marincola

*Joint with the conference on **Purinergic Signaling***

The conference will focus on immune escape mechanisms, immune tolerance, the role of immune effector and suppressor cells as well as the tumor microenvironment in this context, and the modulation of these different processes. The meeting is expected to attract a broad range of scientists (e.g., biologists, biochemists, immunologists, cancer researchers) and clinicians (oncologists, pathologists, radiologists) and will bridge basic, translational and clinical research. There will be a strong clinical focus to the program, in particular regarding different therapeutic strategies including cancer immunotherapy and targeted therapies, which have recently been successfully implemented for the therapy of many cancers including chronic myeloid leukemia, breast carcinoma, non-small lung carcinoma, colorectal cancer, kidney cancer and melanoma.

Session Topics:

- Tumor Microenvironment and Effector Cells
- Immune Signature and Biomarkers
- System Biology and Dysregulation in Cancer
- Cancer Immunotherapy:
Adoptive T Cell Transfer and Cell Therapy
- Targeted Therapies and Combination Therapies
- Immune Suppression and the Role of Paracrine Factors in Modulating Immune Suppression
- Novel Immunotherapeutic Approaches and Antibody Therapies
- Immune Escape Mechanisms by Immune Suppressive Cells/Factors



Submitting an abstract is a great way of participating in the conference through poster presentation and possible selection for a short talk.

Scholarship & Discounted Abstract Deadline: Sep 29, 2015

Abstract Deadline: Oct 29, 2015

Discounted Registration Deadline: Nov 24, 2015

For additional details, visit www.keystonesymposia.org/16J6.

KEYSTONE SYMPOSIA™
on Molecular and Cellular Biology
Accelerating Life Science Discovery

www.keystonesymposia.org/meetings | 1.800.253.0685 | 1.970.262.1230

a 501(c)(3) nonprofit educational organization

KEYSTONE SYMPOSIA

on Molecular and Cellular Biology

Cancer Immunotherapy: Immunity and Immunosuppression Meet Targeted Therapies (J6)

Scientific Organizers: Barbara Seliger, Jerome Galon and Francesco M. Marincola

Sponsored by BioLegend, Inc., Genentech, Inc., Genmab A/S, ImmunoGen, Inc., Incyte Corporation, Infinity Pharmaceuticals, Inc., Merck & Co., Inc., Mersana Therapeutics, MorphoSys AG, Pfizer Inc., Regeneron Pharmaceuticals, Inc., Sanofi US, Shire Human Genetic Therapies and Thermo Fisher Scientific Inc.

Purinergic Signaling (J5)

Scientific Organizers: Joel Linden, Mark J. Smyth, Simon C. Robson and Kenneth A. Jacobson

January 24-28, 2016 • Fairmont Hotel Vancouver • Vancouver, British Columbia, Canada

Sponsored by Bayer HealthCare Pharmaceuticals and Roche

Abstract & Scholarship Deadline: September 29, 2015 / Abstract Deadline: October 29, 2015 / Discounted Registration Deadline: November 24, 2015

SUNDAY, JANUARY 24

Arrival and Registration

MONDAY, JANUARY 25

Welcome, Video Greeting from Dr. Geoffrey Burnstock and Keynote Address (Joint)

***Barbara Seliger**, Martin Luther University, Germany

***Joel Linden**, La Jolla Institute for Allergy and Immunology, USA

Simon C. Robson, Beth Israel Deaconess Medical Center, USA
Purinergic Signaling and Conditioning of Inflammatory Responses in Clinical Disease

Robert D. Schreiber, Washington University School of Medicine, USA
Personalizing Cancer Immunotherapy

Tumor Microenvironment and Effector Cells (J6)

***Jerome Galon**, INSERM UMRS1138, Cordeliers Research Center, France

Thomas Blankenstein, Max Delbruck Center for Molecular Medicine, Germany
Adoptive T Cell Therapy

Barbara Seliger, Martin Luther University, Germany
Escape of Tumors from Immune Cell Recognition by Modulating MHC Class I Antigen Processing Components

Fathia Mami-Chouaib, Institut Gustave Roussy, France
Paradoxical Role of TGF-beta in Promoting CTL Effector Functions within Epithelial Tumor Microenvironment by Triggering CD103 Integrin Expression and Signaling

David C. Clever, National Institutes of Health, USA
Short Talk: Inhibition of T Cell Oxygen Sensing Promotes Pulmonary Effector Responses and Limits Tumor Metastasis

Purine Release (J5)

***Gerhard Dahl**, University of Miami, USA
ATP Release through Pannexon Channels.

Christa E. Müller, Universität Bonn, Germany
Medicinal Chemistry of Purinergic Signalling

Leon J. DeLalio, University of Virginia, USA
Short Talk: Localization of Panx1 to Caveolae Facilitates ATP Release in the Vasculature

Marta Radwan, University of Bath, UK
Short Talk: The Mouse Pannexin1-P2X7 Receptor Interactome

Francesco Di Virgilio, University of Ferrara, Italy
ATP: A Novel Constituent of the Tumor Microenvironment affecting Tumor Growth and Metastatic Spreading

Workshop (J6)

***Jerome Galon**, INSERM UMRS1138, Cordeliers Research Center, France

Matthew Coelho, University College London - The Francis Crick Institute, UK

Oncogenic RAS Signaling Promotes Tumor Immuno-resistance by Stabilizing PD-L1 mRNA

Daniel Corey, Stanford University, USA

Reverse Engineering B. Schlosser's Developmental-regulated Cell Death Programs for Cancer Immunotherapy

Mirjana Efreмова, Medical University of Innsbruck, Austria
Modeling Immunoediting of the Tumor during Progression

Mirjam H.M. Heemskerk, Leiden University Medical Center, Netherlands

TCR Gene Therapy Targeting the Intracellular Transcription Factor Bob1 for the Treatment of Multiple Myeloma

Nikhil S. Joshi, Yale University School of Medicine, USA

Investigating Endogenous Anti-tumor T Cell Responses in Native Tumor Microenvironments

Rachel Yamin, Hebrew University, Israel

Profiling of Ubiquitin Modifications in NK Cell Activation

Iryna Saranchova, University of British Columbia, Canada
Molecular Studies on the Primary to Metastatic Transition

Workshop 1: ATP Release and Metabolism (J5)

***Brant Isakson**, University of Virginia, USA

***Gennady G. Yegutkin**, University of Turku, Finland

Alexander S. Keller, University of Virginia, USA
Expression of Pannexin Isoforms in Mouse Erythrocytes

Miranda E. Good, University of Virginia, USA
Smooth Muscle Cell Pannexin1 can Regulate Myogenic Reactivity in Cerebral Arteries

Kishio Furuya, Nagoya University, Japan
Stretch Induced ATP Release via Hemichannels Accelerates Wound Closure in Keratinocyte by Ca²⁺ Influx from TRPC6

Juan Pablo Huidobro-Toro, Universidad de Santiago de Chile, Chile
A Potassium Rich Diet Increased Mechanically Evoked ATP Release from Rat Mesenteric Endothelial Cells; Clinical Implications

Christian Renn, University of Bonn, Germany
Comparison of ecto-5'-nucleotidase (CD73) Assays for the Identification and Characterization of Inhibitors

Florian Wirsdörfer, University Hospital Essen, Germany
Role of CD73 and Extracellular Adenosine in Radiation-Induced Lung Fibrosis

Gilles Kauffenstein, Angers University, France
Vascular Changes in Pseudoxanthoma Elasticum - Potential Link to Extracellular Purine Metabolism

Maria Serena Longhi, Beth Israel Deaconess Medical Center, USA
Aberrant Regulation of CD39 Expression by Th17 Cells in Inflammatory Bowel Disease

KEYSTONE SYMPOSIA

on Molecular and Cellular Biology

Cancer Immunotherapy: Immunity and Immunosuppression Meet Targeted Therapies (J6)

Scientific Organizers: Barbara Seliger, Jerome Galon and Francesco M. Marincola

Sponsored by BioLegend, Inc., Genentech, Inc., Genmab A/S, ImmunoGen, Inc., Incyte Corporation, Infinity Pharmaceuticals, Inc., Merck & Co., Inc., Mersana Therapeutics, MorphoSys AG, Pfizer Inc., Regeneron Pharmaceuticals, Inc., Sanofi US, Shire Human Genetic Therapies and Thermo Fisher Scientific Inc.

Purinergic Signaling (J5)

Scientific Organizers: Joel Linden, Mark J. Smyth, Simon C. Robson and Kenneth A. Jacobson

January 24-28, 2016 • Fairmont Hotel Vancouver • Vancouver, British Columbia, Canada

Sponsored by Bayer HealthCare Pharmaceuticals and Roche

Abstract & Scholarship Deadline: September 29, 2015 / Abstract Deadline: October 29, 2015 / Discounted Registration Deadline: November 24, 2015

Immune Signature and Biomarkers (J6)

***Barbara Seliger**, Martin Luther University, Germany

Jerome Galon, INSERM UMRS1138, Cordeliers Research Center, France

Importance of the Immune Infiltration and Cancer Classification

Francesco M. Marincola, Sidra Medical and Research Center, Qatar
A Panoramic View of Tumor Rejection Induced by Immune Therapy

Ton N. Schumacher, Netherlands Cancer Institute, Netherlands
T Cell Recognition and Tumor Resistance in Human Cancer

Daniela Schmid, Dana-Farber Cancer Institute, USA
Short Talk: T Cell-Targeted Nanoparticles for Delivery of Immunomodulatory Molecules

Purine Metabolism (J5)

***Norbert Sträter**, University of Leipzig, Germany
Structure and Function of CD39 and CD73 in Purinergic Signalling

***Elizabeth Hartland**, University of Melbourne, Australia
Microbial NTPDases and their role during infection

Ridong Chen, APT Therapeutics, Inc., USA
Human Apyrase as a Paradigm-shifting Therapy for Cardiovascular Diseases with Undetectable Bleeding Risk

Cynthia St. Hilaire, University of Pittsburgh, USA
Short Talk: In Vivo Disease Modeling Using Patient-Derived iPSCs: CD73-Deficiency Promotes Osteogenic Differentiation and Calcification

Poster Session 1

TUESDAY, JANUARY 26

Systems Biology and Dysregulation in Cancer (J6)

***Francesco M. Marincola**, Sidra Medical and Research Center, Qatar

James P. Allison, University of Texas MD Anderson Cancer Center, USA

Tumor Targeting using Checkpoint Antibodies

Carlo M. Croce, Ohio State University, USA
Causes and Consequences of microRNA Dysregulation in Cancer

Ofer Mandelboim, Hebrew University, Israel
Importance of Bacteria in Modulating NK Cell Response against Tumors

Francesca Finotello, Biocenter, Medical University of Innsbruck, Austria

Short Talk: Quantification of Tumor-Infiltrating Lymphocyte Subpopulations using Imaging and Sequencing Data

Spencer C. Wei, University of Texas MD Anderson Cancer Center, USA

Short Talk: High-Dimensional Cytometry Reveals Novel T cell Populations that Arise in the Absence of CTLA-4

Adenosine and P2Y Structure and Medicinal Chemistry (J5)

***Mark Yeager**, University of Virginia School of Medicine, USA
Structural Biology of Adenosine Receptor G-Protein Complexes

Stefano Moro, University of Padova, Italy
Short Talk: Could Adenosine Engage its Receptors with an Alternative 1:1 Stoichiometry? New Insights from Supervised Molecular Dynamics (SuMD) Simulations

Ruben Abagyan, University of California, San Diego, USA
Modeling and Structure Based Discovery of Allosteric Modulators

Edward P. Amento, Molecular Medicine Research Institute, USA
Short Talk: Positive Allosteric Modulation of the Adenosine A2a Receptor Alleviates PMA-Induced Acute Contact Dermatitis in Mice

***Kodi S. Ravichandran**, University of Virginia, USA
Don't Let Death Do Us Part: Pannexin Channels in Communication between Apoptotic Cells and Phagocytes

***Kenneth A. Jacobson**, NIDDK, National Institutes of Health, USA
Structure-Based Design of P2Y Receptor Ligands

Poster Session 2

Workshop 2: Purinergic Receptors and Cancer (J5)

***Silvia Deaglio**, University of Turin, Italy

***Simon C. Robson**, Beth Israel Deaconess Medical Center, USA
Sara Serra, University of Turin and Human Genetics Foundation, Italy
Adenosine Signaling Mediates Hypoxic Responses in the Chronic Lymphocytic Leukemia (CLL) Microenvironment

Bruce Cronstein, New York University, USA
Ticagrelor Inhibits Spread of Multiple Myeloma to Bone

Jessica Lynn Bowser, University of Texas MD Anderson Cancer Center, USA

CD73 Mediates Epithelial Integrity in Endometrial Carcinoma: Is Protecting the Barrier Promoting Tumor Immunosuppression

Amanda S. MacLeod, Duke University, USA
IL-27-Inducible ENTPD1 Suppresses Protective Skin-Resident Immunity upon UV Damage and Inhibits DNA Repair

Odd Lilleng Gammelgaard, University of Southern Denmark, Denmark
Dual Epitope Targeting of CD73 Exhibits Potent Anti-Cancer Activity

Daniela Sauma, Universidad de Chile, Chile
CD73-Mediated Adenosine Production Promotes Stem Cell-Like Properties in Mouse Tc17 Cells

Miki Kamiyama, University of Tokyo, Japan
ASK1 Regulates Tumor Lung Metastasis and Platelet Functions through ADP Signaling

KEYSTONE SYMPOSIA

on Molecular and Cellular Biology

Cancer Immunotherapy: Immunity and Immunosuppression Meet Targeted Therapies (J6)

Scientific Organizers: Barbara Seliger, Jerome Galon and Francesco M. Marincola

Sponsored by BioLegend, Inc., Genentech, Inc., Genmab A/S, ImmunoGen, Inc., Incyte Corporation, Infinity Pharmaceuticals, Inc., Merck & Co., Inc., Mersana Therapeutics, MorphoSys AG, Pfizer Inc., Regeneron Pharmaceuticals, Inc., Sanofi US, Shire Human Genetic Therapies and Thermo Fisher Scientific Inc.

Purinergic Signaling (J5)

Scientific Organizers: Joel Linden, Mark J. Smyth, Simon C. Robson and Kenneth A. Jacobson

January 24-28, 2016 • Fairmont Hotel Vancouver • Vancouver, British Columbia, Canada

Sponsored by Bayer HealthCare Pharmaceuticals and Roche

Abstract & Scholarship Deadline: September 29, 2015 / Abstract Deadline: October 29, 2015 / Discounted Registration Deadline: November 24, 2015

Cancer Immunotherapy: Adoptive T Cell Transfer and Cell Therapy (J6)

***Thomas Blankenstein**, Max Delbrück Center for Molecular Medicine, Germany

Nicholas P. Restifo, NCI, National Institutes of Health, USA
Curative Immunotherapy Using CAR- and TCR-Based T Cells

Gerold Schuler, University Hospital of Erlangen, Germany
Monocyte-Derived Dendritic Cells as Vaccines: Beyond Simple Induction of T Cells

Ronald Levy, Stanford University, USA
Targeting the Immune System while Targeting the Cancer Customized vs. Off-the-Shelf Therapies

Karl-Johan Malmberg, Radiumhospitalet, Norway
Short Talk: Critical Role of CD2 Co-Stimulation in Adaptive NK Cell Responses Revealed in NKG2C-Deficient Humans

Drugs Targeting Adenosine Receptors (J5)

***Bruce Cronstein**, New York University, USA

Tomyuki Kanda, Kyowa Hakko Kirin Co., Ltd., Japan
Adenosine A2A Receptor as Therapeutic Target for Parkinson's and Neurodegeneration

Joel Linden, La Jolla Institute for Allergy and Immunology, USA
Inhibition of Sterile Inflammation by Adenosine

***Pnina Fishman**, Can-Fite BioPharma Ltd., Israel
Utilizing the A3 Adenosine Receptor as a Target to Combat Cancer: From Lab to Labeling

Carmen Corciulo[†], New York University Medical Center, USA
Short Talk: Adenosine A2A Receptor, But Not A2B Receptor, Deletion Leads to Development of Osteoarthritis (OA) in Mice and Administration of a Liposomal Suspension of Adenosine Prevents/Treats Osteoarthritis in Rats

WEDNESDAY, JANUARY 27

Immune Suppression and the Role of Paracrine Factors in Modulating Immune Suppression (J6)

***Rolf Kiessling**, Karolinska Institute, Sweden

Sandra Demaria, Weill Cornell Medical College, USA
Harnessing Radiotherapy to Overcome Tumor Resistance to Immunotherapy

Joel Le Maoult, Institut Universitaire d'Hématologie, France
Role of HLA-G in Human Tumors

Sjoerd H. van der Burg, Leiden University Medical Center, Netherlands
HLA-E in Cancer: From Immune Escape to Therapeutic Target?

Erik Thiele Orberg, Johns Hopkins School of Medicine, USA
Short Talk: The Myeloid Immune Signature of Enterotoxigenic Bacteroides fragilis-induced Murine Colon Tumorigenesis

Byron Kwan, Massachusetts Institute of Technology, USA
Short Talk: Integrin-targeted Combination Immunotherapy Improves Survival in a Broad Spectrum of Tumor Types

Cancer Immunotherapy I (J5)

***Joel Linden**, La Jolla Institute for Allergy and Immunology, USA

Gennady G. Yegutkin, University of Turku, Finland
Cellular Purine Homeostasis as a Complex and Coordinated Network Controlling Tumor Invasion and Migration

John Stagg, University of Montréal, Canada
CD73-mediated Adenosine Signaling in Human Cancers

***Michail Sitkovsky**, Northeastern University, USA
Conceptually Novel "Anti-Hypoxia-A2A-Adenosinergic" Checkpoint Inhibitors to Improve Immunotherapies and Chemotherapies of Cancer

Caglar Cekic, Bilkent University, Turkey
Adenosine Regulation of Myeloid Cells in Solid Tumors

Erik Wennerberg, Weill Cornell Medical College, USA
Short Talk: Adenosine Regulates Radiation Therapy-Induced Anti-Tumor Immunity

Arabella Young, QIMR Berghofer Medical Research Institute, Australia
Short Talk: Co-inhibition of Adenosine Generation and Signaling Improves Anti-Tumour Immune Responses

Novel Immunotherapeutic Approaches and Antibody Therapies (J6)

***Michele Maio**, University Hospital of Siena, Italy

Gregory Lawrence Beatty, University of Pennsylvania, USA
Activating Innate and Adaptive Immunity by CD40 Agonists

Nils Lonberg, Bristol-Myers Squibb, USA
Immune Checkpoints and Combination Therapy

Susanne Steggerda, Calithera Biosciences, Inc., USA
Short Talk: Arginase Inhibitor CB-1158 is a Novel Immuno-Oncology Agent that Targets Tumor-Infiltrating Suppressive Myeloid Cells

Cancer Immunotherapy II (J5)

***John Stagg**, University of Montréal, Canada

Kris F. Sachsenmeier, MedImmune LLC, USA
MEDI9447: Targeting CD73 in the Tumor Microenvironment

Phillip K. Darcy, Peter MacCallum Cancer Centre, Australia
Enhancing Adoptive Cellular Therapy by Targeting Tumor-Induced Immunosuppression

***Mark J. Smyth**, QIMR Berghofer Medical Research Institute, Australia
Strategies for Combination Cancer Immunotherapies that Target Adenosine

KEYSTONE SYMPOSIA

on Molecular and Cellular Biology

Cancer Immunotherapy: Immunity and Immunosuppression Meet Targeted Therapies (J6)

Scientific Organizers: Barbara Seliger, Jerome Galon and Francesco M. Marincola

Sponsored by BioLegend, Inc., Genentech, Inc., Genmab A/S, ImmunoGen, Inc., Incyte Corporation, Infinity Pharmaceuticals, Inc., Merck & Co., Inc., Mersana Therapeutics, MorphoSys AG, Pfizer Inc., Regeneron Pharmaceuticals, Inc., Sanofi US, Shire Human Genetic Therapies and Thermo Fisher Scientific Inc.

Purinergic Signaling (J5)

Scientific Organizers: Joel Linden, Mark J. Smyth, Simon C. Robson and Kenneth A. Jacobson

January 24-28, 2016 • Fairmont Hotel Vancouver • Vancouver, British Columbia, Canada

Sponsored by Bayer HealthCare Pharmaceuticals and Roche

Abstract & Scholarship Deadline: September 29, 2015 / Abstract Deadline: October 29, 2015 / Discounted Registration Deadline: November 24, 2015

Dora Hammerl, La Jolla Institute, USA

Short Talk: Intratumoral Injection of Microparticles Containing the A2A Receptor Antagonist SCH58261 Slow Tumor Growth and Metastasis More Effectively than Systemic Drug Administration

Poster Session 3

THURSDAY, JANUARY 28

Immune Escape Mechanisms by Immune Suppressive Cells/Factors (J6)

Thomas Gajewski, University of Chicago, USA
Molecular Mechanisms of the T Cell-Inflamed Tumor Microenvironment: Implications for Immunotherapy

Rolf Kiessling, Karolinska Institute, Sweden
Counteracting Tumor-Induced Immune Suppression by Checkpoint Blockade and Inhibitors of CSF-R1

David H. Munn, Georgia Regents University, USA
IDO, PTEN and Activated Tregs in the Tumor Microenvironment

Robert Leone, Johns Hopkins University School of Medicine, USA
Role of Metabolic Changes on the Immune Response

Robbert M. Spaapen, Sanquin Research, Netherlands
Short Talk: Intramolecular MHC Class I Regulation Affects Functional Antigen Presentation

Anushka Dongre, Whitehead Institute for Biomedical Research, USA
Short Talk: Understanding the Contribution of the Epithelial to Mesenchymal Transition (EMT) to Immuno-suppression in Breast Carcinomas

Purinergic Signaling in the CNS (J5)

***Kazuhide Inoue**, Kyushu University, Japan
Purinergic Regulation of Microglia in Neuropathic Pain

***Maria P. Abbracchio**, University of Milan, Italy
Purinergic Regulation of Oligodendrocyte Precursor Cells and Myelination

Masahiro Mishina, Nippon Medical School, Japan
Brain Imaging of Adenosine Receptors

Francisco J. Quintana, Harvard Medical School, USA
Control of Autoimmune Inflammation by CD39 (ENTPD1)

Mallikarjunarao Ganesana, University of Virginia, USA
Short Talk: Increase of Transient Adenosine Release Frequency from Ischemic Brain

Catia Lambertucci, University of Camerino, Italy
Short Talk: Partial Agonists of A1 Adenosine Receptors as Neuroprotective Agents

Workshop 3: P2 Purinergic Receptors as Drug Targets (J5)

***Kenneth A. Jacobson**, NIDDK, National Institutes of Health, USA

***Christa E. Müller**, Universität Bonn, Germany

Aranzazu M. Mediero, New York University School of Medicine, USA

Ticagrelor Regulates Osteoblast and Osteoclast Function and Promotes Bone Formation in Vivo via an Adenosine Dependent Mechanism

Guido Beldi, University of Bern, Switzerland
P2X1 Regulated IL-22 Secretion by Innate Lymphoid Cells is Required for Efficient Liver Regeneration

Stephanie Weinhausen, University of Bonn, Germany
Binding Site of the Allosteric P2X4 Receptor Modulator Ivermectin

Ronald Sluyter, University of Wollongong, Australia
P2X7 Receptor Activation Mediates Amyotrophic Lateral Sclerosis-Associated Mutant Superoxide Dismutase 1 Release from Murine Motor Neurons

Friedrich Koch-Nolte, University Medical Center Hamburg-Eppendorf, Germany
Nanobodies That Block Gating of the P2X7 ion Channel Ameliorate Inflammation

Alicia Mathers, University of Pittsburgh, USA
Signaling Through the P2X7 Receptor Induces an Acute Psoriasis-Like Inflammatory Response in the Skin

Mabrouka Salem, Laval University, Canada
P2Y6 Receptor Deletion Exacerbates Intestinal Inflammation Through Th17 Recruitment

Angela Schulz, University Leipzig, Medical Faculty, Germany
P2Y14 Influences Insulin Secretion

Targeted Therapies and Combination Therapies (J6)

***Barbara Seliger**, Martin Luther University, Germany

Adrian Bot, Kite Pharma, Inc., USA
Optimizing the Translation of Genetically Programmed T Cells to Safe and Potent Therapies

Leisha A. Emens, Johns Hopkins School of Medicine, USA
Enhancing Cancer Vaccine Activity with Tumor-Specific Monoclonal Antibodies

Michele Maio, University Hospital of Siena, Italy
Sequential Therapy of Checkpoint Inhibitors with Targeted Therapies

P2 Receptors (J5)

***Friedrich Koch-Nolte**, University Medical Center Hamburg-Eppendorf, Germany

***Rosaria Volpini**, Università degli Studi di Camerino, Italy
P2 Receptor Ligands: Overview and Updates

Marco Cattaneo, Università degli Studi di Milano, Italy

***Kenneth A. Jacobson**, NIDDK, National Institutes of Health, USA

FRIDAY,
JANUARY
29

Departure

KEYSTONE SYMPOSIA

on Molecular and Cellular Biology

Cancer Immunotherapy: Immunity and Immunosuppression Meet Targeted Therapies (J6)

Scientific Organizers: Barbara Seliger, Jerome Galon and Francesco M. Marincola

Sponsored by BioLegend, Inc., Genentech, Inc., Genmab A/S, ImmunoGen, Inc., Incyte Corporation, Infinity Pharmaceuticals, Inc., Merck & Co., Inc., Mersana Therapeutics, MorphoSys AG, Pfizer Inc., Regeneron Pharmaceuticals, Inc., Sanofi US, Shire Human Genetic Therapies and Thermo Fisher Scientific Inc.

Purinergic Signaling (J5)

Scientific Organizers: Joel Linden, Mark J. Smyth, Simon C. Robson and Kenneth A. Jacobson

January 24-28, 2016 • Fairmont Hotel Vancouver • Vancouver, British Columbia, Canada

Sponsored by Bayer HealthCare Pharmaceuticals and Roche

Abstract & Scholarship Deadline: September 29, 2015 / Abstract Deadline: October 29, 2015 / Discounted Registration Deadline: November 24, 2015

marco Cattaneo, Università degli Studi di Milano, Italy
P2Y₁₂ Receptors: Structure and Function

Mufeng Li, NINDS, National Institutes of Health, USA
Structure and Gating Mechanisms of ATP Activated P2X Receptor Channels

Meeting Wrap-Up: Outcomes and Future Directions (Organizers) (J6)

Meeting Wrap-Up: Outcomes and Future Directions (J5)